share_log

TransMedics | 10-Q: Q3 2024 Earnings Report

TransMedics | 10-Q: Q3 2024 Earnings Report

TransMedics | 10-Q:2024財年三季報
美股SEC公告 ·  2024/10/29 20:24

牛牛AI助理已提取核心訊息

TransMedics Group reported strong Q3 2024 financial results with total revenue reaching $108.8 million, up 64% year-over-year, driven by significant growth in both product and service revenue. Net income was $4.2 million compared to a net loss of $25.4 million in Q3 2023. Product revenue grew to $65.9 million while service revenue from the National OCS Program (NOP) increased to $42.9 million.The company's U.S. OCS transplant revenue surged to $104.9 million, up from $59.7 million last year, with particularly strong growth in OCS Liver and Heart segments. Gross margin was 56%, with product gross margin at 80% and service gross margin at 19%. Operating expenses increased to $56.9 million as the company continued investing in commercial expansion and R&D.TransMedics maintained a strong balance sheet with $330.1 million in cash as of September 30, 2024. The company expanded its logistics capabilities through aircraft acquisitions and pilot hiring to support NOP growth. Management indicated continued focus on scaling manufacturing operations, developing next-generation OCS technology, and growing the commercial team to drive further market penetration.
TransMedics Group reported strong Q3 2024 financial results with total revenue reaching $108.8 million, up 64% year-over-year, driven by significant growth in both product and service revenue. Net income was $4.2 million compared to a net loss of $25.4 million in Q3 2023. Product revenue grew to $65.9 million while service revenue from the National OCS Program (NOP) increased to $42.9 million.The company's U.S. OCS transplant revenue surged to $104.9 million, up from $59.7 million last year, with particularly strong growth in OCS Liver and Heart segments. Gross margin was 56%, with product gross margin at 80% and service gross margin at 19%. Operating expenses increased to $56.9 million as the company continued investing in commercial expansion and R&D.TransMedics maintained a strong balance sheet with $330.1 million in cash as of September 30, 2024. The company expanded its logistics capabilities through aircraft acquisitions and pilot hiring to support NOP growth. Management indicated continued focus on scaling manufacturing operations, developing next-generation OCS technology, and growing the commercial team to drive further market penetration.
TransMedics集團公佈了2024年第三季度強勁的財務業績,總營業收入達到10880萬美元,同比增長64%,這得益於產品和服務營業收入的顯著增長。凈利潤爲420萬美元,而2023年第三季度的淨虧損爲2540萬美元。產品營業收入增長至6590萬美元,而國家OCS項目(NOP)的服務營業收入則增加至4290萬美元。公司美國OCS移植營業收入猛增至10490萬美元,較去年的5970萬美元大幅增長,特別是在OCS肝臟和心臟領域表現強勁。毛利率爲56%,其中產品毛利率爲80%,服務毛利率爲19%。營業費用增加至5690萬美元,因爲公司繼續投資於商業擴張和研發。截至2024年9月30日,TransMedics保持了強勁的資產負債表,持有現金33010萬美元。公司通過收購飛機和僱用飛行員增強其物流能力,以支持NOP的增長。管理層表示將繼續注重擴大製造業運營,開發下一代OCS科技,並擴大商業團隊以推動進一步的市場滲透。
TransMedics集團公佈了2024年第三季度強勁的財務業績,總營業收入達到10880萬美元,同比增長64%,這得益於產品和服務營業收入的顯著增長。凈利潤爲420萬美元,而2023年第三季度的淨虧損爲2540萬美元。產品營業收入增長至6590萬美元,而國家OCS項目(NOP)的服務營業收入則增加至4290萬美元。公司美國OCS移植營業收入猛增至10490萬美元,較去年的5970萬美元大幅增長,特別是在OCS肝臟和心臟領域表現強勁。毛利率爲56%,其中產品毛利率爲80%,服務毛利率爲19%。營業費用增加至5690萬美元,因爲公司繼續投資於商業擴張和研發。截至2024年9月30日,TransMedics保持了強勁的資產負債表,持有現金33010萬美元。公司通過收購飛機和僱用飛行員增強其物流能力,以支持NOP的增長。管理層表示將繼續注重擴大製造業運營,開發下一代OCS科技,並擴大商業團隊以推動進一步的市場滲透。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 634

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。